PCSK9, LDLR-binding epitope blocking Antibody from EXALPHA BIOLOGICALS, INC.
Search, find, compare suppliers for anti-PCSK9, LDLR-binding epitope blocking antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | PCSK9, LDLR-binding epitope blocking |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | ammonium sulfate precipitate |
| Size | 100 µg |
| Concentration | n/a |
| Applications | ELISA, Western Blotting, ELISA, Western Blotting |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Rabbit anti Human Proprotein convertase subtilisin/kexin type 9 (PCSK9), LDLR-binding epitope blocking |
| Immunogen | Synthetic peptide derived from the human PCSK9 protein reported to block PCSK9-LDLR interaction. |
| Other Names | Proprotein convertase PC9, Subtilisin/kexin-like protease PC9, Neural apoptosis-regulated convertase 1 |
| Gene, Accession # | UniProt: Q8NBP7 |
| Catalog # | X2404P |
| Price | $319 |
| Order / More Info | PCSK9, LDLR-binding epitope blocking Antibody from EXALPHA BIOLOGICALS, INC. |
| Product Specific References | 1. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33. Epub 2003 Jan 27. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Seidah NG, et al 2. Nat Genet. 2003 Jun;34(2):154-6. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Abifadel et al 3. Hum Mutat. 2005 Nov;26(5):497. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Allard D et al 4. Am J Hum Genet. 2006 Mar;78(3):410-22. Epub 2006 Jan 20. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Kotowski IK, et al 5. Clin Genet. 2004 May;65(5):419-22. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Leren TP. 6. PLoS One. 2007 Oct 31;2(10):e1098. Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. Ding K, McDonough SJ, Kullo IJ. 7. J Hum Genet. 2004;49(2):109-14. Epub 2004 Jan 15. Genetic variants in PCSK9 affect the cholesterol level in Japanese. Shioji K, et al 8. Atherosclerosis. 2005 Oct;182(2):331-40. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Graham CA et al 9. Cell. 2006 Nov 3;127(3):635-48. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Olsen J V et al 10. J Am Coll Cardiol. 2005 May 17;45(10):1611-9. Epub 2005 Apr 21. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. Chen SN et al |
EXALPHA BIOLOGICALS, INC.
EXALPHA BIOLOGICALS, INC.
2 Shaker Road, Unit B101
Shirley MA 01464
P: 978-425-1370
info@exalpha.com
https://www.exalpha.com
Profile of EXALPHA BIOLOGICALS, INC.
Return to Antibodies